CA2352361A1 - Pharmaceutical combination preparations of carvedilol and hydrochlorothiazide and the process for their preparation - Google Patents

Pharmaceutical combination preparations of carvedilol and hydrochlorothiazide and the process for their preparation Download PDF

Info

Publication number
CA2352361A1
CA2352361A1 CA002352361A CA2352361A CA2352361A1 CA 2352361 A1 CA2352361 A1 CA 2352361A1 CA 002352361 A CA002352361 A CA 002352361A CA 2352361 A CA2352361 A CA 2352361A CA 2352361 A1 CA2352361 A1 CA 2352361A1
Authority
CA
Canada
Prior art keywords
hydrochlorothiazide
carvedilol
pharmaceutical combination
preparation
combination preparations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002352361A
Other languages
French (fr)
Other versions
CA2352361C (en
Inventor
Rudolf Heller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cheplapharm Arzneimittel GmbH
Original Assignee
F. Hoffmann-La Roche Ag
Rudolf Heller
Cheplapharm Arzneimittel Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8233041&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2352361(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F. Hoffmann-La Roche Ag, Rudolf Heller, Cheplapharm Arzneimittel Gmbh filed Critical F. Hoffmann-La Roche Ag
Publication of CA2352361A1 publication Critical patent/CA2352361A1/en
Application granted granted Critical
Publication of CA2352361C publication Critical patent/CA2352361C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

The present invention is concerned with a pharmaceutical combination preparation for the treatment of cardiac and cardiovascular disorders such as hypertension, angina pectoris, cardiac insufficiency and illnesses associated therewith, containing the active substances carvedilol or a pharmaceutically acceptable salt thereof and hydrochlorothiazide or a pharmaceutically acceptable salt thereof as well as pharmaceutically usual additives.
CA002352361A 1998-11-27 1999-11-20 Pharmaceutical combination preparations of carvedilol and hydrochlorothiazide and the process for their preparation Expired - Lifetime CA2352361C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98122489 1998-11-27
EP98122489.2 1998-11-27
PCT/EP1999/008972 WO2000032174A2 (en) 1998-11-27 1999-11-20 Pharmaceutical combination preparations of carvedilol and hydrochlorothiazide

Publications (2)

Publication Number Publication Date
CA2352361A1 true CA2352361A1 (en) 2000-06-08
CA2352361C CA2352361C (en) 2007-01-02

Family

ID=8233041

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002352361A Expired - Lifetime CA2352361C (en) 1998-11-27 1999-11-20 Pharmaceutical combination preparations of carvedilol and hydrochlorothiazide and the process for their preparation

Country Status (22)

Country Link
US (3) US6403579B1 (en)
EP (1) EP1131072B1 (en)
JP (2) JP2002531395A (en)
KR (1) KR100421347B1 (en)
CN (1) CN1184971C (en)
AR (1) AR020287A1 (en)
AT (1) ATE238056T1 (en)
AU (1) AU765977B2 (en)
BR (1) BR9915610A (en)
CA (1) CA2352361C (en)
CO (1) CO5011053A1 (en)
DE (1) DE69907252T2 (en)
DK (1) DK1131072T3 (en)
ES (1) ES2195638T3 (en)
MY (1) MY121831A (en)
PE (1) PE20001302A1 (en)
PT (1) PT1131072E (en)
TR (3) TR200200982T2 (en)
TW (1) TWI228414B (en)
UY (1) UY25821A1 (en)
WO (1) WO2000032174A2 (en)
ZA (1) ZA200104280B (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20001302A1 (en) * 1998-11-27 2000-11-30 Hoffmann La Roche PREPARATIONS OF A PHARMACEUTICAL COMBINATION CONTAINING CARVEDILOL AND HYDROCHLOROTHIAZIDE
WO2002065834A2 (en) * 2000-10-24 2002-08-29 Smithkline Beecham Corporation Novel formulations of carvedilol
US20030070584A1 (en) 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
IN191028B (en) * 2001-05-17 2003-09-13 Sun Pharmaceutical Ind Ltd
US8309118B2 (en) 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
AU2003231283A1 (en) * 2002-04-30 2003-11-17 Sb Pharmco Puerto Rico Inc. Carvedilol monocitrate monohydrate
WO2004002419A2 (en) 2002-06-27 2004-01-08 Sb Pharmco Puerto Rico Inc. Carvedilol phosphate salts and/or solvates thereof, correspondinq compositions, and/or methods of treatment
WO2004002472A1 (en) 2002-06-27 2004-01-08 Sb Pharmco Puerto Rico Inc. Carvedilol hydrobromide
AU2003275953A1 (en) 2002-11-08 2004-06-07 Egalet A/S Controlled release carvedilol compositions
EP1610767B1 (en) 2003-03-26 2011-01-19 Egalet A/S Morphine controlled release system
WO2004094378A1 (en) * 2003-04-21 2004-11-04 Matrix Laboratories Ltd Process for the preparation of carvedilol form-ii
AU2003272851A1 (en) * 2003-09-26 2005-04-14 Shuyi Zhang Sustained release preparation containing hydrochlorothiazide
EP1686986A4 (en) 2003-11-25 2009-05-27 Sb Pharmco Inc Carvedilol salts, corresponding compositions, methods of delivery and/or treatment
ES2662903T3 (en) * 2003-11-25 2018-04-10 Smithkline Beecham (Cork) Limited Carvedilol-free base, salts, anhydrous or solvate forms thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or administration procedures
US20050169994A1 (en) * 2003-11-25 2005-08-04 Burke Matthew D. Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
PL380065A1 (en) * 2003-12-02 2006-12-11 Nicox S.A. Nitrooxyderivatives of carvedilol and other beta blockers as antihypertensive drugs
RU2007129642A (en) * 2005-02-25 2009-03-27 Ф.Хоффманн-Ля Рош Аг (Ch) TABLETS WITH IMPROVED DISTRIBUTION OF MEDICINE
CA2836545C (en) * 2006-06-16 2016-08-09 Lek Pharmaceuticals D.D. Pharmaceutical composition comprising telmisartan and hydrochlorothiazide
GB0612540D0 (en) * 2006-06-23 2006-08-02 Novartis Ag Galenical formulations of organic compounds
WO2008114276A1 (en) * 2007-03-16 2008-09-25 Lupin Limited Novel oral controlled release composition of carvedilol
AU2008258596B2 (en) 2007-06-04 2013-02-14 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
EP2393484A1 (en) 2009-02-06 2011-12-14 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
CA2766179A1 (en) 2009-06-24 2010-12-29 Egalet Ltd. Controlled release formulations
EP2544723A2 (en) * 2010-03-10 2013-01-16 Giuliani International Limited Compositions for colon lavage and methods of making and using same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2815926A1 (en) 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh NEW CARBAZOLYL- (4) -OXY-PROPANOLAMINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
FR2643556B1 (en) * 1989-02-27 1993-03-05 Sanofi Sa PHARMACEUTICAL COMPOSITION WITH SUSTAINED RELEASE OF VALPROIC ACID
NL9220009A (en) * 1991-01-30 1993-11-01 Wellcome Found WATER-DISPERSIBLE TABLETS.
EP0546593B1 (en) * 1991-10-30 1997-09-03 Glaxo Group Limited Multi-layered compositions containing histamine or serotonin antagonists
TW483763B (en) * 1994-09-02 2002-04-21 Astra Ab Pharmaceutical composition comprising of ramipril and dihydropyridine compound
US5760069A (en) * 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
FR2752162B1 (en) * 1996-08-07 1998-11-06 Jouveinal Lab TRIMEBUTINE FILM MALEATE TABLET
DE19637082A1 (en) * 1996-09-12 1998-03-19 Boehringer Mannheim Gmbh Rapidly disintegrating pellets
PE20001302A1 (en) * 1998-11-27 2000-11-30 Hoffmann La Roche PREPARATIONS OF A PHARMACEUTICAL COMBINATION CONTAINING CARVEDILOL AND HYDROCHLOROTHIAZIDE

Also Published As

Publication number Publication date
US20040087578A1 (en) 2004-05-06
TR200200981T2 (en) 2002-06-21
TR200200982T2 (en) 2002-06-21
DK1131072T3 (en) 2003-08-11
KR20010080578A (en) 2001-08-22
BR9915610A (en) 2001-08-14
WO2000032174A2 (en) 2000-06-08
DE69907252D1 (en) 2003-05-28
AU765977B2 (en) 2003-10-09
AR020287A1 (en) 2002-05-02
ZA200104280B (en) 2002-08-26
WO2000032174A3 (en) 2000-11-16
ATE238056T1 (en) 2003-05-15
MY121831A (en) 2006-02-28
CA2352361C (en) 2007-01-02
JP2007077160A (en) 2007-03-29
US20020052367A1 (en) 2002-05-02
DE69907252T2 (en) 2004-01-29
PT1131072E (en) 2003-08-29
PE20001302A1 (en) 2000-11-30
CN1328460A (en) 2001-12-26
TR200101470T2 (en) 2001-11-21
KR100421347B1 (en) 2004-03-06
UY25821A1 (en) 2001-07-31
AU1506500A (en) 2000-06-19
ES2195638T3 (en) 2003-12-01
EP1131072A2 (en) 2001-09-12
TWI228414B (en) 2005-03-01
EP1131072B1 (en) 2003-04-23
CO5011053A1 (en) 2001-02-28
US6403579B1 (en) 2002-06-11
JP2002531395A (en) 2002-09-24
CN1184971C (en) 2005-01-19

Similar Documents

Publication Publication Date Title
CA2352361A1 (en) Pharmaceutical combination preparations of carvedilol and hydrochlorothiazide and the process for their preparation
CA2401910A1 (en) Hydrophilic molecular disperse solutions of carvedilol
CA2392096A1 (en) Polymorphic form of atorvastatin calcium
CA2259148A1 (en) Solid oral dosage forms of valsartan
TR200000561T2 (en) Therapeutic compounds containing amlodipine and atorvastatin.
CA2349330A1 (en) Nitrogen containing heterobicycles as factor xa inhibitors
HUP9802221A2 (en) Antiparasitic marcfortines and paraherquamides
DE69820287D1 (en) MEDICINAL PRODUCT CONTAINING CLODRONATE AS AN ACTIVE SUBSTANCE AND MICROCRISTALLINE CELLULOSE TREATED WITH SILICON DIOXIDE AS A FILLER
NO890075D0 (en) PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE IMIDAZOLS.
CA2339991A1 (en) Microemulsions as solid dosage forms for oral administration
WO2002094774A3 (en) Oxcarbazepine dosage forms
CA2270177A1 (en) Transdermal administration of ment
CA2296637A1 (en) Thermodynamically stable modification of 1-(4-carbazolyloxy)-3-[2-(2-methoxyphenoxy)ethylamino]-2-propanole, process for its preparation and pharmaceutical compositions containingit
WO2003015779A3 (en) Matrix controlled transdermal therapeutic system for the use of pramipexole and ropinirole
CA2164776A1 (en) Pharmaceutical, orally applicable composition
EA200000360A1 (en) ORAL COMPOSITIONS OF LEVOSIMENDAN
EE200000014A (en) Process for the preparation of (+) - norcisapride base, (+) - norcisapride, its pharmaceutically acceptable acid addition salt and their use, pharmaceutical composition and process for its preparation and intermediate
RU93047023A (en) ANIMOTENZINE-11 IMIDAZOLE ANTAGONISTS DERIVATIVES, THEIR PRODUCTION AND THERAPEUTIC USE
WO2003045327A3 (en) Efavirenz tablet formulation having unique biopharmaceutical characteristics
CA2236641A1 (en) Preparation of fagopyritols and uses therefor
AU3955199A (en) Remedies for itching containing PGD2 antagonists
CA2282279A1 (en) Atropisomers of 3-heteroaryl-4(3h)-quinazolinones for the treatment of neurodegenerative and cns-trauma related conditions
CA2348474A1 (en) Pharmaceutically active composition and dispensing device
HUP0400889A3 (en) Processes for the preparation of (r)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol and pharmaceutical compositions containing the compound
CA2376847A1 (en) Complex of eletriptan and a cyclodextrin derivative

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20191120